title: Intranuclear translocation of phospholipase C beta2 during HL-60 myeloid differentiation.
abstract: Phospholipases C (PLC) beta3, gamma1, and gamma2 were detected in nuclei of HL-60 promyelocitic leukaemia cells. When HL-60 cells undergo terminal myeloid differentiation in the presence of ATRA, the beta2 isoform appeared inside nuclei and was up-regulated until 72 hours of ATRA treatment. The beta3 isozyme was also increased until 72 hours and both isoforms lowered their intranuclear amount at 96 hours and following days of treatment. By contrast PLC gamma1 and gamma2 progressively increased in the nucleus during granulocytic differentiation even after 72 hours of treatment. Terminal differentiation was characterised by the expression of high levels of PLC gamma1 and gamma2 and by low levels of PLC beta2 and beta3 in the nucleus. PIP2 and PIP hydrolysis paralleled the prevalence of the beta or gamma subfamily, respectively. Moreover, at all the examined times no changes of PLCs in the whole cell were detectable, indicating a de novo nuclear translocation of the beta2 and an increased accumulation of beta3, gamma1, and gamma2 isoforms. Thus, the intranuclear presence, expression, and activity of PLC isozymes, which are modulated during differentiation of HL-60 cells, implicate a role for nuclear phosphoinositide signalling in the process of cell maturation. In particular the nuclear translocation of PLC beta2 candidates this PLC as a key enzyme in the granulocytic differentiative commitment of HL-60 cells.
authors.affiliation: Signal Transduction Unit/Laboratory of Cell Biology, Institute of Human Anatomy, University of Ferrara, Italy.
authors.forename: V
authors.initials: V
authors.lastname: Bertagnolo
authors.forename: M
authors.initials: M
authors.lastname: Marchisio
authors.forename: S
authors.initials: S
authors.lastname: Capitani
authors.forename: L M
authors.initials: LM
authors.lastname: Neri
mesh_terms: D002454:Cell Differentiation; D002467:Cell Nucleus / Q000201:enzymology*; D003600:Cytosol / Q000201:enzymology; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006098:Granulocytes / Q000166:cytology* / Q000187:drug effects / Q000201:enzymology; D018922:HL-60 Cells / Q000166:cytology* / Q000201:enzymology; D006801:Humans; D007527:Isoenzymes / Q000096:biosynthesis*; D007700:Kinetics; D054799:Phospholipase C beta; D051966:Phospholipase C gamma; D013997:Time Factors; D014212:Tretinoin / Q000494:pharmacology*; D010738:Type C Phospholipases / Q000096:biosynthesis*
chemical_list: D007527:Isoenzymes; D014212:Tretinoin; D010738:Type C Phospholipases; C518036:PLCB2 protein, human; C518039:PLCB3 protein, human; D054799:Phospholipase C beta; D051966:Phospholipase C gamma